Skin Biophysical Measures for Assessing Head and Neck Cancer-Related External Lymphedema
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Skin tissue dielectric constant (TDC) measurements will non-invasively be made bilaterally at two neck sites, bilaterally on two forearm sites and one site at the chin sub-mental area.
Measurements are made with subjects fully clothed and seated. Measurements are made in triplicate and averaged at each site. Full measurements take about 5-7 minutest to complete. Data will be analyzed to determine the neck-to-arm ratios and chin-to-arm ratios to establish normal ranges of these parameters for subsequent use as comparisons to evaluate and track changes in patients with head and neck lymphedema.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33328
- Nova Southeastern University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy with no current or past skin conditions affecting neck or arms
Exclusion Criteria:
- Known to have diabetes of any type.
- Having facial or neck hair that prohibits accurate measurements
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy Adults
Healthy
|
measurements
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neck-to-Arm TDC ratio
Time Frame: one year
|
Neck-to-Arm TDC ratio
|
one year
|
|
Sub-Mental-to-Arm TDC ratio
Time Frame: one year
|
Sub-Mental-to-Arm TDC ratio
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bilateral values and Variability in TDC values
Time Frame: one year
|
Bilateral values and Variability in TDC values
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-595-NSU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphedema, Secondary
-
NCT06606145CompletedLymphedema | Lymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema Arm | Lymphedema of Arm
-
NCT02988505CompletedPrimary Lymphedema Secondary Lymphedema
-
NCT04252690CompletedLymphedema, Secondary | Lymphedema of Leg | Lymphedema Congenital | Lymphedema Primary
-
NCT04858230TerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema Arm
-
NCT04196725Completed
-
NCT04045860CompletedSecondary Lymphedema | Lymphedema of Face
-
NCT05485454CompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema Primary
-
NCT01748604CompletedSecondary Lymphedema | Primary Lymphedema
-
NCT05242900Active, not recruitingLymphedema, Secondary | Lymphedema of Leg | Lymphedema Related Fibrosis
-
NCT04393168CompletedLymphedema | Secondary Lymphedema
Clinical Trials on TDC
-
NCT04561297Completed
-
NCT05709873CompletedNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2
-
NCT03366116RecruitingNeoplasms | Solid Tumors
-
NCT01201629TerminatedBrain Ischemia | Brain Infarction
-
NCT02748746Withdrawn
-
NCT02685995CompletedRenal Failure Chronic Requiring Hemodialysis | Chronic Renal Insufficiency
-
NCT06405282CompletedPerfusion; Complications | Fluid Retention Tissue
-
NCT03709550WithdrawnCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | PSA Level Greater Than or Equal to Two
-
NCT02257138CompletedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White Cells